RA Capital teams swept first and second place in Inner City Weightlifting’s “2021 Fittest Company Challenge.” How’d we do it? Because our teams embodied so many of the values that make RA Capital great.

Covid has flooded a barren vaccine startup landscape with capital. And that has revealed some valuable lessons for investors, company builders, Congress, and the public.

As more established targeted protein degradation companies produce promising data in the clinic, newcomers have been greeted with sustained enthusiasm from the investment community. Here we revisit a few key intellectual and scientific breakthroughs & focus on molecular glues as an exciting new frontier.

The story of Alexander Fleming is a popular one. As it should be - it’s a good story about one of the most important discoveries in medical history, penicillin. But most people only know the first act of the play.

In this month’s episode of RA TV, we look back at the past year for biotech, examine today’s headlines, and contemplate the future of this pandemic — and maybe the next one.

LENZ Therapeutics CEO Eef Schimmelpennink spoke with RApport about how last year’s acquisition of Pfenex by Ligand gave him a chance to seek out a new challenge, the benefits of breaking the mold, and helping 120 million Americans ditch their reading glasses.

In biotech - an industry where companies live or die by the success of a lead asset - how much impact does a successful management team have? And more broadly, how should we define success? Is it a matter of stock price? The ability to drive an acquisition? Do your employees even like you as a person?

Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.

If the Biden drug plan passes, the United States will be consciously volunteering to put less capital to work in a large industry where we lead the world. No real argument can stand against the fact that less capital means fewer new products for patients.

Given the seemingly endless supply of COVID-19-related content, it has sometimes felt like I was passively binging on round-the-clock coverage that was more distracting than edifying. So what might I have missed while I was absorbed in COVID? As it turns out, quite a lot.

The U.S. biotechnology sector is an indispensable, strategic national asset. But what if we’re taking it for granted? Recent attempts to weaken IP protections for Covid-19 vaccines and to implement drug price controls threaten future U.S. leadership in biotechnology.

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

The way that hospitals benefit from inflated list prices is a common theme across different kinds of drugs dispensed at hospitals and clinics across the country. When drug prices are a Trojan Horse for all kinds of other health care costs, we all lose.

Listen in as RA Capital’s TechAtlas Associates convene to discuss recent Covid-19 news. Learn about the emerging Delta variant, new data from Novavax and CureVac, and the potential association between mRNA vaccines and myocarditis.

There are many ways to conduct an efficient board meeting, and every management team and board member has different preferences. But here are four key principles I believe will improve everyone’s experience.

To be sure, none of these can ensure death with dignity, but most will speed your start-up’s demise – especially when taken as combination therapy.

The so-called venture creation model has fully taken root, underpinned and enabled by biotech's longest-ever boom cycle and unprecedented sums of available capital.

Adam Rosenberg lifts the curtain on what biotech venture partners and entrepreneurs-in-residence really do.

We’re glad you’re here. Read more about the genesis of RApport and our mission and goals.